Condition: Antiphospholipid Syndrome · Arterial Thrombosis · Sponsor: McMaster University
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.
This description comes directly from the study's public registry record.
Sam Schulman, MD, PhD · +19055270271 · schulms@mcmaster.ca
Hannah Cohen, MD, FRCP · +442034477368 · hannah.cohen@ucl.ac.uk
Always discuss trial participation with your own doctor first.
| Instituto de Investigaciones en Salud Pública, Universidad de Buenos Aires | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
| Clinica Universitaria Reina Fabiola | Córdoba, Argentina | Recruiting |
| McMaster University | Hamilton, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05646394